Thalidomide is Used for treating multiple myeloma and erythema nodosum leprosum. It was first introduced by Bristol-Myers Squibb Co in its drug Thalomid on Jul 16, 1998. 2 different companies have introduced drugs containing Thalidomide.

Thalidomide Patents

Given below is the list of patents protecting Thalidomide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Thalomid	US5629327	Methods and compositions for inhibition of angiogenesis	May 13, 2014 (Expired)	Bristol-myers
Thalomid	US6045501	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol-myers
Thalomid	US6235756	Methods and compositions for inhibition of angiogenesis by thalidomide	Mar 01, 2013 (Expired)	Bristol-myers
Thalomid	US6315720	Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug	Oct 23, 2020 (Expired)	Bristol-myers
Thalomid	US6561976	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol-myers
Thalomid	US6561977	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol-myers
Thalomid	US6755784	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol-myers
Thalomid	US6869399	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol-myers
Thalomid	US6908432	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol-myers
Thalomid	US7141018	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol-myers
Thalomid	US7230012	Pharmaceutical compositions and dosage forms of thalidomide	Dec 09, 2023 (Expired)	Bristol-myers
Thalomid	US7435745	Methods and compositions for inhibition of angiogenesis	Nov 03, 2017 (Expired)	Bristol-myers
Thalomid	US7723361	Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide	Mar 01, 2013 (Expired)	Bristol-myers
Thalomid	US7874984	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol-myers
Thalomid	US7959566	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol-myers
Thalomid	US8143283	Methods for treating blood-born tumors with thalidomide	Mar 01, 2013 (Expired)	Bristol-myers
Thalomid	US8204763	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol-myers
Thalomid	US8315886	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol-myers
Thalomid	US8589188	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol-myers
Thalomid	US8626531	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol-myers

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Thalidomide's patents.

Latest Legal Activities on Thalidomide's Patents

Given below is the list recent legal activities going on the following patents of Thalidomide.

Event	Date	Patent/Publication
Today's Legal Activities
Expire Patent	17 Jul, 2023	US7959566
Expire Patent	27 Feb, 2023	US7874984
Maintenance Fee Reminder Mailed	30 Jan, 2023	US7959566
Maintenance Fee Reminder Mailed	12 Sep, 2022	US7874984
Expire Patent	16 Nov, 2020	US7435745(Litigated)
Maintenance Fee Reminder Mailed	01 Jun, 2020	US7435745(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity	14 Dec, 2018	US7959566
Payment of Maintenance Fee, 12th Year, Large Entity	12 Dec, 2018	US7230012(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity	25 Jul, 2018	US7874984
Payment of Maintenance Fee, 12th Year, Large Entity	29 May, 2018	US7141018

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳